IDEC Pharma sees Rituxan sales leap 115% in 1st qtr 2001
IDEC Pharmaceuticals says that first-quarter 2001 sales revenuesincreased 109.3% to $56.5 million, with net income rising to $20.8 million, compared with a loss of $4.3 million in first-quarter 2000. The company's revenues included $48.6 million from its joint business arrangement with Genentech for the commercialization of Rituxan (rituximab), up 115% year-on-year.
IDEC also received a $5 million milestone payment from Schering AG upon filing a marketing authorization application on Zevalin (ibritumomab) in Europe. The firm expects to receive notification of a complete review letter from the US Food and Drug Administration on or before May 3 on the filing status of Zevalin (Marketletter April 2).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze